June 26, 2015

Boston Globe

Three Bay State biotechs go public in IPOs

Seres Therapeutics Inc., a Cambridge biotech developing a new class of drugs to treat infections and metabolic disorders, is set to make its debut as a publicly traded company Friday after raising nearly $134 million in an initial public offering.

The company was one of three Massachusetts life sciences startups that went public this week as the strong IPO market of the past two years extended into mid-2015.

Read more: http://www.bostonglobe.com/business/2015/06/26/ipos/STeMIWQgxEOPKqb9cOJhvM/story.html